Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

Ying-Xia Ning; Xin Luo; Meng Xu; Xin Feng; Jian Wang

doi:10.18632/oncotarget.20413

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

Ying-Xia Ning, Xin Luo, Meng Xu, Xin Feng and Jian Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:74836-74845. https://doi.org/10.18632/oncotarget.20413

Metrics: PDF 1459 views | HTML 2405 views | ?

Abstract

Ying-Xia Ning1,2,*, Xin Luo2, Meng Xu2,*, Xin Feng3,* and Jian Wang4

1Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

2The First Affiliated Hospital of Jinan University, Guangzhou 510632, China

3Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou 510315, China

4Institute of Reproductive and Stem Cell Engineering, Central South University, National Engineering and Research Center of Human Stem Cell, Changsha, 41007, China

*These authors have contributed equally to this work

Correspondence to:

Jian Wang, email: [email protected]

Xin Luo, email: [email protected]

Keywords: ovarian cancer, c-Myc, let-7d, genistein analogue, PI3K/AKT

Received: October 26, 2016 Accepted: June 02, 2017 Published: August 23, 2017

ABSTRACT

c-Myc is a key oncogenic transcription factor that participates in tumor pathogenesis. In this study, we found that levels of c-Myc mRNA and protein were higher in early ovarian cancer tissues than normal ovary samples. Increased c-Myc levels correlated positively with clinical stage I (Ia+b/Ic) in ovarian cancer patients. Patients with higher nuclear c-Myc expression had shorter overall survival times than patients with low c-Myc expression. Knocking down c-Myc sensitized ovarian cancer cells to 7-difluoromethoxyl-5,4’-di-n-octylgenistein (DFOG), a novel synthetic genistein analogue that suppressed PI3K/AKT signaling in vitro and in vivo. Finally, c-Myc was confirmed to be a direct target of let-7d, and let-7d-induced suppression of c-Myc increased the DFOG-sensitivity of ovarian cancer cells. These results indicate that nuclear c-Myc expression is an unfavorable factor in early ovarian cancer, and that let-7d increases ovarian cancer cell sensitivity to DFOG by suppressing c-Myc and PI3K/AKT signaling.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20413

Publication Alerts

Research Papers:

Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc

Abstract